With the introduction of immunomodulatory anticancer therapies such as antibodies against PD-L1 and CTLA-4, as well as an increased understanding of the importance of immune activation in the response to chemotherapeutic agents, research into immunity within the tumor microenvironment (TME) has continued to evolve [2]. The gene discussed is CTLA4; the disease is neoplasm.